FIRST AMENDMENT TO LICENSE AGREEMENT NO. 2000-03-0591
QuickLinks -- Click here to rapidly navigate through this document
FIRST AMENDMENT
TO
LICENSE AGREEMENT NO. 0000-00-0000
This First Amendment is made and is effective this 18th day of May 2000 (the Effective Date) by and between The Regents of the University of California ("The Regents"), a California corporation having its statewide administrative offices at 0000 Xxxxxxxx Xxxxxx, 00xx Xxxxx, Xxxxxxx, Xxxxxxxxxx 00000-0000, acting through the offices of The University of California, Los Angeles located at 00000 Xxxxxxxx Xxxx., Xxxxx 0000, Xxx Xxxxxxx, Xxxxxxxxxx 00000-0000, and Prometheus Laboratories, Inc. ("Prometheus"), a California corporation having a principal place of business at 0000 Xxxxxxx Xxxxxx Xxxxxxxxx, Xxx Xxxxx, Xxxxxxxxxx 00000 and amends the License Agreement dated December 1, 1999 (the "Agreement").
Whereas Exhibit A defining Regents and Cedars-Sinai Medical Center Joint Inventions Patent Rights is amended to include an invention known as "Diagnosis, Prevention and Treatment of Crohn's Disease Using the OmpC Antigen (UC Case No. 2000-451-1) developed by Xxxxxxxx Xxxxx at the University of California, Los Angeles and Xxxxxxx Xxxxxx, at Cedar-Sinai Medical Center et al. A patent application based on this technology was filed in the U.S. Patent and Trademark Office on May 19, 2000, Serial Number to be advised.
All other terms and conditions remain the same.
| Prometheus Laboratories, Inc. | |||
By: |
/s/ Xxxxxxx X. Xxxxx Xxxxxxx X. Xxxxx, President & Chief Executive Officer |
6-8-00 Date |
|
The Regents of the University of California |
|||
By: |
/s/ Xxxxx Xxxxxxx Xxxxx Xxxxxxx Xx. Technology Transfer Officer Office of Intellectual Property Admin. |
6-7-00 Date |
|
